Drug, across the briefings
Lisocabtagene Maraleucel across 8 cancers
Lisocabtagene Maraleucel appears in 8 of the briefings; its FDA label names 5 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Chronic lymphocytic leukemia | label names disease | approved on CD19 | 4 | 3 |
| Diffuse large B-cell lymphoma | label names disease | approved on CD19 | 13 | 7 |
| Follicular lymphoma | label names disease | approved on CD19 | 10 | 4 |
| Mantle cell lymphoma | label names disease | approved on CD19 | 1 | 0 |
| Marginal zone lymphoma | label names disease | — | — | |
| Acute lymphoblastic leukemia | approved on CD19 | — | — | |
| Burkitt lymphoma | approved on CD19 | — | — | |
| Waldenström macroglobulinaemia | approved on CD19 | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.